Allovir, INC 8-K filings

Kalaris Therapeutics announced second quarter 2026 financial results, reporting $93.5 million in cash and ongoing patient dosing in its Phase 1b/2 study for TH103, with preliminary data anticipated in 1H 2027.

Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, while Brett Hagen resigns as Chief Accounting Officer.

Kalaris Therapeutics announced positive additional data from its Phase 1a SAD clinical trial of TH103 for neovascular age-related macular degeneration (nAMD), showing improvements in vision and retinal anatomy.

Kalaris Therapeutics announced the resignation of director Morana Jovan-Embiricos and the election of Laurie Keating to the board and audit committee, effective August 1, 2026.

Kalaris Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of new directors and the ratification of its independent auditor.

Kalaris Therapeutics reports Q1 2026 financial results, highlighting $104.9 million in cash reserves and progress in its Phase 1b/2 study for TH103.

Kalaris Therapeutics announced the resignation of its Chief Financial Officer, Matthew Gall, effective April 14, 2026, with Chief Accounting Officer Brett Hagen assuming principal financial officer duties.

Kalaris Therapeutics announced full-year 2025 financial results, highlighted by positive initial Phase 1a data for TH103 and a $50.0 million private placement, extending its cash runway into Q4 2027.

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, announced an oversubscribed private placement raising approximately $50.0 million to advance its lead retinal disease candidate, TH103.

Kalaris Therapeutics announced positive initial Phase 1a data for its TH103 treatment for neovascular age-related macular degeneration, demonstrating significant visual and anatomic improvements and potential for extended durability.

Kalaris Therapeutics announced its third-quarter 2025 financial results and provided updates on its TH103 clinical development program, including ongoing Phase 1a and newly initiated Phase 1b/2 trials.

Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall, a seasoned biopharmaceutical finance executive, as its new Chief Financial Officer and Treasurer, effective November 3, 2025.

Kalaris Therapeutics, Inc. announced the successful election of two Class II directors and the ratification of Deloitte & Touche LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Kalaris Therapeutics announced its second quarter 2025 financial results, highlighting continued enrollment in its Phase 1 TH103 trial for nAMD and expecting initial clinical data in Q4 2025.

Kalaris Therapeutics, Inc. has announced its 2025 annual meeting of stockholders will be held on August 12, 2025, with specific deadlines set for shareholder proposals and director nominations due to the change in meeting date.

Kalaris Therapeutics announced its Q1 2025 financial results, highlighting progress in the Phase 1 trial of TH103 for nAMD and a strong cash position following its merger with AlloVir.

Kalaris Therapeutics has entered into an employment agreement with CEO Andrew Oxtoby and an offer letter amendment with SVP and Chief Accounting Officer Brett Hagen, outlining compensation and severance terms.

Kalaris Therapeutics has appointed Leone Patterson to its Board of Directors and as Chair of the Audit Committee, effective immediately.

Napoco, Inc. establishes an equity incentive plan to attract, retain, and motivate eligible individuals through stock-based awards.

AlloVir stockholders have approved the proposed merger with Kalaris Therapeutics, with the combined company expected to trade under the ticker symbol 'KLRS' on the Nasdaq Capital Market.

AlloVir, Inc. has executed a 1-for-23 reverse stock split of its common stock, effective January 15, 2025, to comply with Nasdaq listing requirements and in connection with a proposed merger.

AlloVir's board has approved a 1-for-23 reverse stock split, set to take effect on January 15, 2025, as part of its merger with Kalaris Therapeutics.

AlloVir stockholders have approved a reverse stock split proposal, allowing the board to enact a split between 1-for-15 and 1-for-35 before January 10, 2026.

AlloVir, Inc. has announced the departure of CEO Diana Brainard, with current President and CFO Vikas Sinha stepping into the role, effective December 19, 2024.

AlloVir and Kalaris Therapeutics have agreed to merge in an all-stock transaction, creating a company focused on developing treatments for retinal diseases.

AlloVir, Inc. has terminated its lease agreement for its Waltham, MA premises, incurring a $7 million payment to the landlord.

AlloVir, Inc. has terminated its sublease agreement for its Waltham, Massachusetts office space, incurring a $5.7 million termination fee.

AlloVir, Inc. held its annual meeting on June 6, 2024, where stockholders elected three Class I directors and ratified the appointment of Deloitte & Touche LLP as the company's independent auditor for the fiscal year ending December 31, 2024.

AlloVir's board has approved potential $100,000 cash bonuses for its CEO, CFO, and General Counsel, contingent on a change of control transaction in 2024.

AlloVir, Inc. received a notice from Nasdaq for failing to maintain a minimum stock price of $1.00, triggering a potential delisting process.